Manzanares-Guzman A, Alfonseca-Ladron de Guevara A, Reza-Escobar E, Burciaga-Flores M, Canales-Aguirre A, Esquivel-Solis H
Int J Mol Sci. 2025; 26(3).
PMID: 39940647
PMC: 11817625.
DOI: 10.3390/ijms26030876.
Liu J, Wu L, Xie A, Liu W, He Z, Wan Y
J Nanobiotechnology. 2025; 23(1):87.
PMID: 39915791
PMC: 11800653.
DOI: 10.1186/s12951-025-03169-5.
Duan Z, Li D, Li N, Lin S, Ren H, Hong J
Mol Ther Oncol. 2024; 32(4):200892.
PMID: 39524212
PMC: 11546159.
DOI: 10.1016/j.omton.2024.200892.
Xu M, Zhao Z, Deng P, Sun M, Chiu C, Wu Y
Int J Mol Sci. 2024; 25(18).
PMID: 39337289
PMC: 11432006.
DOI: 10.3390/ijms25189801.
Shoemaker R, Larsen R, Larsen P
Front Immunol. 2024; 15:1426656.
PMID: 39238639
PMC: 11374656.
DOI: 10.3389/fimmu.2024.1426656.
Single-cell RNA sequencing illuminates the ontogeny, conservation and diversification of cartilaginous and bony fish lymphocytes.
Wang H, Chen J, Li Y, Zhang X, Liu X, Lu Y
Nat Commun. 2024; 15(1):7627.
PMID: 39227568
PMC: 11372145.
DOI: 10.1038/s41467-024-51761-4.
Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons.
Rizk S, Moustafa D, ElBanna S, Nour El-Din H, Attia A
World J Microbiol Biotechnol. 2024; 40(7):209.
PMID: 38771414
PMC: 11108896.
DOI: 10.1007/s11274-024-03990-4.
vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.
Manzanares-Guzman A, Lugo-Fabres P, Camacho-Villegas T
Antibodies (Basel). 2024; 13(1).
PMID: 38534215
PMC: 10967338.
DOI: 10.3390/antib13010025.
Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy.
Smyth P, Ferguson L, Burrows J, Burden R, Tracey S, Herron U
Front Pharmacol. 2023; 14:1296567.
PMID: 38116078
PMC: 10728302.
DOI: 10.3389/fphar.2023.1296567.
Structure and Dynamics Guiding Design of Antibody Therapeutics and Vaccines.
Fernandez-Quintero M, Pomarici N, Fischer A, Hoerschinger V, Kroell K, Riccabona J
Antibodies (Basel). 2023; 12(4).
PMID: 37873864
PMC: 10594513.
DOI: 10.3390/antib12040067.
Design and Construction of Antibody Fusion Proteins Incorporating Variable New Antigen Receptor (VNAR) Domains.
Ludwig S, Zhu A, Maremanda A, Dooley H, Spangler J
Methods Mol Biol. 2023; 2720:17-33.
PMID: 37775655
DOI: 10.1007/978-1-0716-3469-1_2.
Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?.
Jiang X, Sun L, Hu C, Zheng F, Lyu Z, Shao J
Mar Drugs. 2023; 21(9).
PMID: 37755109
PMC: 10532743.
DOI: 10.3390/md21090496.
Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours.
Li D, Wang R, Liang T, Ren H, Park C, Tai C
Nat Commun. 2023; 14(1):5920.
PMID: 37739951
PMC: 10517151.
DOI: 10.1038/s41467-023-41631-w.
CDR3 Variants of the TXB2 Shuttle with Increased TfR1 Association Rate and Enhanced Brain Penetration.
Stocki P, Szary J, Demydchuk M, Northall L, Rasmussen C, Logan D
Pharmaceutics. 2023; 15(3).
PMID: 36986599
PMC: 10051654.
DOI: 10.3390/pharmaceutics15030739.
Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?.
Tsitokana M, Lafon P, Prezeau L, Pin J, Rondard P
Int J Mol Sci. 2023; 24(3).
PMID: 36768953
PMC: 9916958.
DOI: 10.3390/ijms24032632.
Humanization of the Shark V Single Domain Antibody Using CDR Grafting.
Zhang Y, Sun Y, Hong J, Ho M
Curr Protoc. 2023; 3(1):e630.
PMID: 36594750
PMC: 9813873.
DOI: 10.1002/cpz1.630.
Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins.
Yu C, Ding W, Zhu L, Zhou Y, Dong Y, Li L
iScience. 2022; 26(1):105736.
PMID: 36570769
PMC: 9771723.
DOI: 10.1016/j.isci.2022.105736.
Research progress on unique paratope structure, antigen binding modes, and systematic mutagenesis strategies of single-domain antibodies.
Liu C, Lin H, Cao L, Wang K, Sui J
Front Immunol. 2022; 13:1059771.
PMID: 36479130
PMC: 9720397.
DOI: 10.3389/fimmu.2022.1059771.
Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.
Valdovino-Navarro B, Duenas S, Flores-Acosta G, Gasperin-Bulbarela J, Bernaldez-Sarabia J, Cabanillas-Bernal O
Int J Mol Sci. 2022; 23(20).
PMID: 36293124
PMC: 9603574.
DOI: 10.3390/ijms232012267.
Application of recombinant antibodies for treatment of infection: Current status and future perspective.
Raeisi H, Azimirad M, Nabavi-Rad A, Aghdaei H, Yadegar A, Zali M
Front Immunol. 2022; 13:972930.
PMID: 36081500
PMC: 9445313.
DOI: 10.3389/fimmu.2022.972930.